Ventrus Biosciences VTUS is trading sgnificantly lower on the session after it announced that the results from pivotal phase 3 trial of Iferanserin (VEN 309) did not meet endpoints. Ventrus Biosciences said it does not have immediate plans to continue development of VEN 309.
Russell H. Ellison, M.D., M.Sc., Chairman and Chief Executive Officer of Ventrus Biosciences said, "We would like to thank both investigators and patients for their support and participation in this study and in the VEN 309 program. The outcome of our Phase 3 study comes as a surprise and a disappointment, particularly given the strong evidence of activity in our Phase 2 randomized study."
Ventrus Biosciences $5.68, a loss of $6.58 or 53.69%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Intraday UpdateMovers
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in